| | At times, our partners reach out to US Income Report with special opportunities for our readers. The message below is one we think you should take a close, serious look at. | | |
| Dear Fellow Investor,
The challenge in treating Alzheimer's isn't the lack of drugs. It's that you can't get those drugs to reach the brain.
You see, the Blood-Brain-Barrier stops 100% of large-molecule drugs from getting to the brain. Small-molecule drugs only fare slightly better. 98% can't make it past the Blood-Brain-Barrier.
Nature does this in order to protect the brain. So the question is -
How do we ever cure Alzheimer's when our drugs can't even reach the brain?
On October 29, 2013, a Jeff Bezos-backed biotech had a radical idea: to employ a "drug smuggler" to help cross the blood-brain-barrier.
Big Pharma giants Biogen, Genentech and Sanofi were so stunned when it worked, they spent $1 billion for the rights to the treatment.
Never before has so much money invested in a single company so quickly.
Jim Cramer estimates this breakthrough would create the "Biggest Drug in the World."
We think this stock could rise 10,000% - if it's not taken over first.
There's just no way Big Pharma would let this company stay independent.
Pfizer, Novartis and Johnson & Johnson make billions selling Alzheimer's drugs each year. They have the most to lose. It's too much of a threat to their business.
That's why this tiny biotech is my #1 Biotech Stock for November.
"The Buck Stops Here," | |  | | | |
|
Post a Comment
Post a Comment